| 1 |
2020 |
Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse. |
ADM, Hh, PDAC |
| 2 |
2020 |
Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells. |
IFN, PDAC, TKI, TLR |
| 3 |
2020 |
Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer. |
KPC, OXPHOS, PDAC |
| 4 |
2020 |
Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. |
IPMN, IPMNs, OS, PanIN, PFS |
| 5 |
2019 |
Circumventing senescence is associated with stem cell properties and metformin sensitivity. |
PDAC |
| 6 |
2019 |
High-grade precursor lesions can be used as surrogate markers to identify the epicenter of periampullary carcinomas. |
BilINs |
| 7 |
2019 |
Karyopherin Alpha 2-Expressing Pancreatic Duct Glands and Intra-Islet Ducts in Aged Diabetic C414A-Mutant-CRY1 Transgenic Mice. |
KPNA2, PDGs, Tg mice |
| 8 |
2019 |
MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). |
IHC, MSP, PanIN, PDAC, PSCs, RON |
| 9 |
2019 |
Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. |
HFD, PDAC, rhFGF21 |
| 10 |
2019 |
Prevention and Reversion of Pancreatic Tumorigenesis through a Differentiation-Based Mechanism. |
--- |
| 11 |
2019 |
PRSS1 mutation: a possible pathomechanism of pancreatic carcinogenesis and pancreatic cancer. |
--- |
| 12 |
2019 |
Spheroid Culture of Human Pancreatic Ductal Cells to Reconstitute Development of Pancreatic Intraepithelial Neoplasia. |
PDA |
| 13 |
2018 |
ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma inMice. |
ATP, IPMNs, PDACs, PDCs |
| 14 |
2018 |
c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. |
CSCs, PDAC |
| 15 |
2018 |
Cells of origin of pancreatic neoplasms. |
IPMNs, MCNs, PDAC |
| 16 |
2018 |
Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury. |
KP, KPS, TMA |
| 17 |
2018 |
Kruppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. |
ADM, KLF5, PDACs |
| 18 |
2018 |
Precursor Lesions of Pancreatic Cancer. |
IOPNs, IPMNs, ITPNs, MCNs, PDAC |
| 19 |
2018 |
Relationship between pancreatic intraepithelial neoplasias, pancreatic ductal adenocarcinomas, and single nucleotide polymorphisms in autopsied elderly patients. |
PDACs, SNPs |
| 20 |
2018 |
SALL4 suppresses reactive oxygen species in pancreatic ductal adenocarcinoma phenotype via FoxM1/Prx III axis. |
EMT, PDAC, ROS, SALL4 |
| 21 |
2018 |
SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. |
ADM, HPNE, MCMs, MDC1, PDAC |
| 22 |
2018 |
The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. |
AGEs, CTR, PaC, PDA, RAGE, RAP |
| 23 |
2017 |
Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression. |
PDAC |
| 24 |
2017 |
ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. |
AGR2, CP, CSC, ER, KC, PDAC, PDX, TC |
| 25 |
2017 |
hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms. |
IPMNs, LNA-ISH, PDAs |
| 26 |
2017 |
Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and Apoptosis. |
P-KrasG12D, PDAC |
| 27 |
2017 |
Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. |
PC |
| 28 |
2017 |
MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression. |
miRNAs, PDAC |
| 29 |
2017 |
Neat1 is a p53-inducible lincRNA essential for transformation suppression. |
ChIP, lincRNA, ncRNA |
| 30 |
2017 |
Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. |
--- |
| 31 |
2017 |
The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cells. |
ChIP, MCAM, PDAC |
| 32 |
2016 |
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. |
--- |
| 33 |
2016 |
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. |
MADM |
| 34 |
2016 |
The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-beta1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-beta1. |
Nrf2, PDAC, TGF-beta1 |
| 35 |
2016 |
The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. |
IHC, KD, PC |
| 36 |
2016 |
The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. |
PDAC, VMP1 |
| 37 |
2015 |
Acinar cell reprogramming: a clinically important target in pancreatic disease. |
PDAC |
| 38 |
2015 |
Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer. |
CP |
| 39 |
2015 |
Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression. |
--- |
| 40 |
2015 |
Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. |
CP, LNA-ISH, PDAC |
| 41 |
2015 |
GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. |
IPMNs, MCNs, PDAs |
| 42 |
2015 |
Gradual telomere shortening and increasing chromosomal instability among PanIN grades and normal ductal epithelia with and without cancer in the pancreas. |
--- |
| 43 |
2015 |
Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). |
PDA |
| 44 |
2015 |
Pancreatic cancer stromal biology and therapy. |
--- |
| 45 |
2015 |
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. |
mTOR, PI3K |
| 46 |
2015 |
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. |
5-LOX, COX-2, EGRF, NGS, PDAC |
| 47 |
2014 |
Investigation of Schwann cells at neoplastic cell sites before the onset of cancer invasion. |
GFAP, NGF, NI |
| 48 |
2014 |
Loss of HNF6 expression correlates with human pancreatic cancer progression. |
HNF6, PDAC |
| 49 |
2014 |
MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. |
MAPK |
| 50 |
2014 |
Polarization of the vacuolar adenosine triphosphatase delineates a transition to high-grade pancreatic intraepithelial neoplasm lesions. |
EGF, LRP6, V-ATPase |
| 51 |
2013 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. |
PRC1 |
| 52 |
2013 |
Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas. |
IPMNs, p-ezrin |
| 53 |
2013 |
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. |
IPMNs |
| 54 |
2013 |
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. |
IPMNs |
| 55 |
2013 |
Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. |
--- |
| 56 |
2012 |
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. |
PDAC |
| 57 |
2012 |
Chemoprevention of pancreatic cancer-one step closer. |
--- |
| 58 |
2012 |
Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. |
CT, GEM, MRI, PDAC, PET, SPECT, US |
| 59 |
2012 |
Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. |
5-LOX, PDAC |
| 60 |
2012 |
Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. |
CSCs, PDAC |
| 61 |
2012 |
Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. |
IER3, NUPR1, PDAC |
| 62 |
2011 |
Claudin-18 is an early-stage marker of pancreatic carcinogenesis. |
CLDN18, IPMNs, MCNs, PDACs, PMA |
| 63 |
2011 |
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. |
--- |
| 64 |
2011 |
GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. |
DAs, IPMNs |
| 65 |
2011 |
Loss of heterozygosity status of D9S105 marker is associated with downregulation of Kruppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. |
KLF4, LOH, OS, PDAC |
| 66 |
2011 |
Pancreatic Intraepithelial Neoplasia. |
--- |
| 67 |
2011 |
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. |
PDAC |
| 68 |
2011 |
Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. |
PC |
| 69 |
2010 |
Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. |
AGR2, IPMNs |
| 70 |
2010 |
Genomic instability at both the base pair level and the chromosomal level is detectable in earliest PanIN lesions in tissues of chronic pancreatitis. |
ADM, CP, LOH, PC |
| 71 |
2010 |
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. |
--- |
| 72 |
2008 |
BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. |
IPMNs |
| 73 |
2008 |
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. |
COX-2 |
| 74 |
2008 |
Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). |
PanIN |
| 75 |
2008 |
Multicentric pancreatic intraepithelial neoplasias (PanINs) presenting with the clinical features of chronic pancreatitis. |
PanIN |
| 76 |
2008 |
Pancreatic intraepithelial neoplasms in the normal appearing pancreas: on their precise relationship with age. |
--- |
| 77 |
2007 |
15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. |
5-LOX, RT-PCR |
| 78 |
2007 |
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. |
PDA |
| 79 |
2007 |
Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. |
IPMNs |
| 80 |
2007 |
Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. |
--- |
| 81 |
2007 |
Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. |
PDAC, SPAG-1 |
| 82 |
2007 |
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. |
PDAC |
| 83 |
2006 |
Current topics on precursors to pancreatic cancer. |
IPMNs, MCNs |
| 84 |
2006 |
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. |
COX-2 |
| 85 |
2005 |
Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. |
--- |
| 86 |
2005 |
Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy. |
--- |
| 87 |
2004 |
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. |
IPMNs |
| 88 |
2004 |
Chronic exposure of transforming growth factor beta 1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells. |
IMPE, TGF-beta1 |
| 89 |
2004 |
Proliferative activity in pancreatic intraepithelial neoplasias of chronic pancreatitis resection specimens: detection of a high-risk lesion. |
--- |
| 90 |
2003 |
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. |
--- |
| 91 |
2003 |
Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. |
IPMNs, JAK/STAT, SOCS-1 |
| 92 |
2003 |
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. |
--- |
| 93 |
2003 |
p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. |
--- |
| 94 |
2003 |
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. |
--- |
| 95 |
2003 |
Surveillance for familial pancreatic cancer. |
PC |
| 96 |
2003 |
The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. |
IPMNs, MUCs |
| 97 |
2002 |
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. |
--- |
| 98 |
2000 |
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. |
--- |
A Search Service for Abbreviation / Long Form
